
    
      30 patients distributed in 3 groups of 10 patients with specific inclusion criteria will
      participate in this trial:

        -  10 MS patients in early disease onset,

        -  10 MS patients under Natalizumab treatment

        -  and control group of 10 patients with other neurological diseases.

      The aim of this clinical trial is to detect the CD8+ myelin specific T-Cells in the blood of
      Multiple Sclerosis patients.
    
  